Showing results (2671-2680 of 6,510) with videos related to
Sort By:
Pageof 651
Contraception|January 24, 2007
The antifertility effectiveness of copper/low-density polyethylene nanocomposite and its influence on the endometrial environment in ratsHe-Fang Liu, Zi-Long Liu, Chang-Sheng Xie, et al.Contraception|March 17, 2007
Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mLCarolyn Westhoff, John K Jain, Ian Milsom, et al.Contraception|March 17, 2007
Treatment satisfaction with a transdermal contraceptive patch or oral contraceptivesGeorge J Wan, Christopher E Barnowski, Baishali M Ambegaonkar, et al.Contraception|March 17, 2007
Contraception and fertility plans in a cohort of HIV-positive women in careNancy L Stanwood, Susan E Cohn, Jennifer R Heiser, et al.Contraception|March 17, 2007
A study of the capability of manufacturers of generic hormonal contraceptives in lower- and middle-income countriesPeter E Hall, Joachim Oehler, Phillip Woo, et al.Contraception|December 13, 2006
Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraceptionLavínia E Borges, Rosires P Andrade, José M Aldrighi, et al.Contraception|December 13, 2006
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenoneHans-Joachim Ahrendt, Israel Nisand, Carlo Bastianelli, et al.Contraception|December 13, 2006
The determinants and circumstances of use of emergency contraceptive pills in France in the context of direct pharmacy accessCaroline Moreau, James Trussell, Nathalie BajosContraception|December 13, 2006
Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trialsDaniel R Mishell, John Guillebaud, Carolyn Westhoff, et al.Contraception|December 13, 2006
Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe)Steven T Nakajima, David F Archer, Herman EllmanPageof 651